Evidence map›Paper›PMID 36497473›Full record

ArticleCancers2022

TRICIN: A Phase II Trial on the Efficacy of Topical TRIchloroacetic Acid in Patients with Cervical Intraepithelial Neoplasia.

Richard Schwameis, Julia Ganhoer-Schimboeck, Victoria Laudia Hadjari, Lukas Hefler, Birgit Bergmeister, Tatjana Küssel, Gunda Gittler, Theodora Steindl-Schoenhuber, Christoph Grimm

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Richard SchwameisDepartment of General Gynecology and Gynecologic Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, 1080 Vienna, Austria.
Julia Ganhoer-SchimboeckDepartment of Obstetrics and Gynecology, Konventhospital Barmherzige Brueder and Ordensklinikum Linz, 4010 Linz, Austria.
Victoria Laudia HadjariDepartment of Obstetrics and Gynecology, Konventhospital Barmherzige Brueder and Ordensklinikum Linz, 4010 Linz, Austria.ORCID 0000-0002-1210-8102
Lukas HeflerDepartment of Obstetrics and Gynecology, Konventhospital Barmherzige Brueder and Ordensklinikum Linz, 4010 Linz, Austria.
Birgit BergmeisterDepartment of Obstetrics and Gynecology, Konventhospital Barmherzige Brueder and Ordensklinikum Linz, 4010 Linz, Austria.
Tatjana KüsselDepartment of Obstetrics and Gynecology, Konventhospital Barmherzige Brueder and Ordensklinikum Linz, 4010 Linz, Austria.
Gunda GittlerBarmherzige Brueder Linz, Hospital Pharmacy, 4020 Linz, Austria.
Theodora Steindl-SchoenhuberBarmherzige Brueder Linz, Hospital Pharmacy, 4020 Linz, Austria.
Christoph GrimmDepartment of General Gynecology and Gynecologic Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, 1080 Vienna, Austria.ORCID 0000-0003-2948-8129
Convent Hospital of the Brothers of Saint John of God · ATComprehensive Cancer Center Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on non-surgical treatment approaching persistent cervical intraepithelial neoplasia (CIN) are scarce. Retrospective analysis suggest high efficacy of topical treatment with trichloroacetic acid (TCA). This prospective phase II study set out to investigate the efficacy of a single application of 85% TCA in the treatment of CIN I/II. Patients with CIN I/II were treated a single time with 85% TCA. After three and six months colposcopic, histologic, and HPV evaluation was performed. The primary endpoint was treatment efficacy defined as complete histologic remission six months after treatment. The secondary endpoint was HPV clearance six months after treatment. A total of 102 patients with CIN I/II were included into this trial. Complete histologic remission rates were 75.5% and 78.4% three and six months after TCA treatment, respectively. Clearance rates of HPV 16, 18 and other high risk types were 76.5%, 91.7%, 68.7% after six months, respectively. Side effects of TCA were mild and lasted usually less than 30 min. This is the first prospective trial reporting high histologic complete remission rates in patients with CIN I/II after a single 85% TCA treatment. In the future, TCA may represent an effective and feasible non-surgical treatment approach for CIN.

Indexed as

cancer preventionCINconizationHPVHSILhuman papilloma viruslarge loop excision of the transformation zoneLSILsquamous cell intraepithelial lesionTCA

Identifiers

PMID36497473
PMCPMC9740961
OpenAlexW4311287461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.